Ascentage Pharma's drugs included in key Chinese oncology guidelines

Ascentage Pharma Group International (HKEX:6855) announced that its proprietary drugs, lisaftoclax (APG-2575) and olverembatinib, are now included in the 2025 Chinese Society of Clinical Oncology (CSCO) Guidelines. Lisaftoclax, an investigational novel oral Bcl-2 selective inhibitor, received its first CSCO Guidelines recommendation for treating Lymphoid Malignancies. Notably, it's the only China-developed Bcl-2 inhibitor recommended in the CSCO Guidelines. Olverembatinib, a novel next-generation tyrosine kinase inhibitor (TKI), received an upgraded recommendation for treating Leukemias in Children and Adolescents, while retaining its recommendation for Hematological Malignancies. In November 2024, the NDA for lisaftoclax (APG-2575) monotherapy for the treatment of R/R CLL/SLL was accepted and granted the Priority Review designation by the Center for Drug Evaluation (CDE) of China National Medical Product Administration (NMPA). The CSCO 2025 Guidelines also upgraded its recommendation for olverembatinib for treating children with Ph+ ALL.